Trento

• A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE Not authorised
  2024-514794-22-01 4 Eosinophilic granulomatosis with polyangiitis (EGPA)
• MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycle Pending
  2022-500308-23-00 11 Infertility in women undergoing assisted reproductive technologies (AR
• Botulinumtoxin type A for treatment of Chronic Pelvic Pain Syndrome (CPPS): a phase 3 randomized, double blind, placebo-controlled, multi-ce … Pending
  2023-506372-27-00 5 Adult patients, male or female, with chronic pelvic pain syndrome (CPP
• A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastat … Pending
  2024-519519-32-00 4 urothelial cancer
• Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T … Pending
  2024-520093-34-00 5 Acinar cell prostatic carcinoma
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimari … Pending
  2025-521651-22-00 4 hormone receptor positive, HER2-negative breast cancer
• A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending
  2025-522084-15-00 10 metastatic NSCLC patients
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis With Polyangiitis Recruiting
  2023-504245-32-00 4 2024-06-06 Eosinophilic granulomatosis with polyangiitis (EGPA)
• A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t … Recruiting
  2022-500461-28-06 5 2022-09-15 High-Risk Metastatic Hormone-Sensitive Prostate Cancer
• A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s … Recruiting
  2024-518223-29-00 4 2020-03-10 Advanced or metastatic untreated EGFR mutation positive NSCLC
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 4 2025-12-17 Prostate Cancer
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro … Recruiting
  2024-520156-22-00 4 2025-10-08 Metastatic hormone-sensitive prostate cancer
• CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE … Recruiting
  2024-517789-41-00 6 2025-07-04 metastatic or locally advanced renal cell carcinoma
• REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting
  2022-502184-38-00 4 2025-06-06 Rapidly progressive glomerulonephritis
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th … Recruiting
  2024-516842-21-00 5 2025-01-09 Recurrent ovarian cancer
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer

Showing 1–24 of 56 trials